TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06692712: Phase 3 Efficacy Study With Concurrent Control of IT MELPIDA in SPG50.Concurrent Controls.

Sponsor: Elpida Therapeutics SPC · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 24 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$1,037,168

Rescue Site Savings

+$707,160

Unlock Full NCT06692712 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06692712 Rescue Dossier →